Abstract
Objective: To review the role of baricitinib and sotrovimab in managing COVID-19, amidst evolving treatment guidelines and varying efficacy against different virus variants. Methodology: This review utilized online database using specific keywords related to the subject independently performed with manual checks of reference lists for completeness. Results: Baricitinib, authorized with remdesivir for severe COVID-19, reduces mechanical ventilation and ICU admissions without increasing hospital stays, and shows improved mortality and recovery rates, especially when combined with corticosteroids. Sotrovimab, effective in early clinical trials at reducing hospitalizations and adverse events, has shown comparable or superior efficacy to other antivirals but lost authorization for variants like Omicron BA.2. Conclusion: Baricitinib works as a JAK inhibitor with a 2 mg dose recommended for COVID-19, while sotrovimab, a monoclonal antibody, neutralizes SARS-CoV-2 but has limitations against certain variants. Both drugs offer significant benefits in treating severe COVID-19.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call